China Biotechnology: Innovation Dawn 2.0: From Wholesale to Bespoke

Research evidence excerpt

China Biotechnology: Innovation Dawn 2.0: From Wholesale to Bespoke

Asia Pacific InsightM

Executive Summary

Core Message:

• Innovation Dawn remains broadly on track: Globalization of China-

originated assets continues, with out-licensing momentum, fundraising,

clinical development, and regulatory progress broadly consistent with our

prior assumptions and forecasts.

• The next phase is from volume to value: The first stage rewarded proof of

global demand. The next should reward companies that retain more

economics and play a larger role in global development.

• Risk allocation explains why China licensing trades below US M&A:

China assets are often earlier-stage, leaving MNCs to bear more overseas

development, data harmonization, translatability, chemistry, manufacturing

and controls (CMC), and commercialization risk.

• Scarcity premium determines who can move up the ladder: Better deal

structures only matter when the asset is differentiated enough to

command stronger economics.

• Stock selection should follow two axes: Risk-bearing capacity, measured

by cash, licensing income, domestic engine, and overseas R&D experience;

and asset scarcity, measured by first-in-class/best-in-class (FIC/BIC)

potential, global relevance, and regulatory portability.

• Names to own: Repeat monetizers where value capture is becoming visible

through stronger retained economics, global execution capability, and

differentiated assets.

• Risks to flag: Geopolitics and US commercialization remain difficult to

internalize near term; NewCo / co-co structures can still dilute value

through funding burden, governance leakage, or weak realization.

Market attention in 2025 focused disproportionately on headline deal value and